Cardio-Oncology for the Primary Care Provider

1 MILLER KD, NOGUEIRA L, DEVASIA T, MARIOTTO AB, YABROFF KR, JEMAL A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022 Sep;72(5):409–436. Search in Google Scholar

2 MANGONE L, MANCUSO P, TARANTINI L, LAROCCA M, BISCEGLIA I, DAMATO A, et al. A Population-Based Study of Cardiovascular Disease Mortality in Italian Cancer Patients. Cancers (Basel). 2021 Nov 24;13(23):5903. Search in Google Scholar

3 SCHINDLER M, SPYCHER BD, AMMANN RA, ANSARI M, MICHEL G, KUEHNI CE; SWISS PAEDIATRIC ONCOLOGY GROUP (SPOG). Cause-specific long-term mortality in survivors of childhood cancer in Switzerland: A population-based study. Int J Cancer. 2016 Jul 15;139(2):322–33. Search in Google Scholar

4 STRONGMAN H, GADD S, MATTHEWS A, MANSFIELD KE, STANWAY S, LYON AR, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019 Sep 21;394(10203):1041–1054. Search in Google Scholar

5 PATERSON DI, WIEBE N, CHEUNG WY, MACKEY JR, PITUSKIN E, REIMAN A, et al. Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study. JACC CardioOncol. 2022 Mar 15;4(1):85–94. Search in Google Scholar

6 CARDINALE D, COLOMBO A, BACCHIANI G, TEDESCHI I, MERONI CA, VEGLIA F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 Jun 2;131(22):1981–8. Search in Google Scholar

7 SMITH LA, CORNELIUS VR, PLUMMER CJ, LEVITT G, VERRILL M, CANNEY P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010 Jun 29;10:337. Search in Google Scholar

8 SAWAYA H, SEBAG IA, PLANA JC, JANUZZI JL, KY B, COHEN V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011 May 1;107(9):1375–80. Search in Google Scholar

9 LYON AR, LÓPEZ-FERNÁNDEZ T, COUCH LS, ASTEGGIANO R, AZNAR MC, BERGLER-KLEIN J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229–4361. Search in Google Scholar

10 ALEXANDRE J, CAUTELA J, EDERHY S, DAMAJ GL, SALEM JE, BARLESI F, et al. Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc. 2020 Sep 15;9(18):e018403. Search in Google Scholar

11 ANANTHAN K, LYON AR. The Role of Biomarkers in Cardio-Oncology. J Cardiovasc Transl Res. 2020 Jun;13(3):431–450. Search in Google Scholar

12 LANCELLOTTI P, SUTER TM, LÓPEZ-FERNÁNDEZ T, GALDERISI M, LYON AR, VAN DER MEER P, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019 Jun 7;40(22):1756–1763. Search in Google Scholar

13 FLORIDO R, DAYA NR, NDUMELE CE, KOTON S, RUSSELL SD, PRIZMENT A, et al. Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll Cardiol. 2022 Jul 5;80(1):22–32. Search in Google Scholar

14 KORIC A, CHANG CP, MARK B, ROWE K, SNYDER J, DODSON M, et al. Cardiovascular disease risk in long-term breast cancer survivors: A population-based cohort study. Cancer. 2022 Jul 15;128(14):2826–2835. Search in Google Scholar

15 PIEPOLI MF, HOES AW, AGEWALL S, ALBUS C, BROTONS C, CATAPANO AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Prev Cardiol. 2016 Jul;23(11):NP1–NP96. Search in Google Scholar

16 CARLSON LE, WATT GP, TONOREZOS ES, CHOW EJ, YU AF, WOODS M, et al. Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer: The WECARE Study. JACC CardioOncol. 2021 Sep 21;3(3):381–392. Search in Google Scholar

17 RAGHUNATHAN D, KHILJI MI, HASSAN SA, YUSUF SW. Radiation-Induced Cardiovascular Disease. Curr Atheroscler Rep. 2017 May;19(5):22. Search in Google Scholar

18 LIU JE, BARAC A, THAVENDIRANATHAN P, SCHERRER-CROSBIE M. Strain Imaging in Cardio-Oncology. JACC CardioOncol. 2020 Dec 15;2(5):677–689. Search in Google Scholar

19 BRADY B, KING G, MURPHY RT, WALSH D. Myocardial strain: a clinical review. Ir J Med Sci. 2022 Nov 16:1–8. Search in Google Scholar

20 LIU JE, BARAC A, THAVENDIRANATHAN P, SCHERRER-CROSBIE M. Strain Imaging in Cardio-Oncology. JACC CardioOncol. 2020 Dec 15;2(5):677–689. Search in Google Scholar

21 MICHEL L, MINCU RI, MAHABADI AA, SETTELMEIER S, AL-RASHID F, RASSAF T, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020 Feb;22(2):350–361. Search in Google Scholar

22 BRACUN V, ABOUMSALLEM JP, VAN DER MEER P, DE BOER RA. Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues. Curr Oncol Rep. 2020 Jun 9;22(7):67. Search in Google Scholar

23 CARDINALE D, COLOMBO A, TORRISI R, SANDRI MT, CIVELLI M, SALVATICI M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010 Sep 1;28(25):3910–6. Search in Google Scholar

24 GOLDENBERG I, MOSS AJ, ZAREBA W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol. 2006 Mar;17(3):333–6. Search in Google Scholar

25 POSTEMA PG, WILDE AA. The measurement of the QT interval. Curr Cardiol Rev. 2014 Aug;10(3):287–94. Search in Google Scholar

26 PORTA-SÁNCHEZ A, GILBERT C, SPEARS D, AMIR E, CHAN J, NANTHAKUMAR K, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017 Dec 7;6(12):e007724. Search in Google Scholar

27 ZAMORANO JL, GOTTFRIDSSON C, ASTEGGIANO R, ATAR D, BADIMON L, BAX JJ, et al. The cancer patient and cardiology. Eur J Heart Fail. 2020 Dec;22(12):2290–2309. Search in Google Scholar

28 BABIKER HM, MCBRIDE A, NEWTON M, BOEHMER LM, DRUCKER AG, GOWAN M, et al. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol. 2018 Jun;126:186–200. Search in Google Scholar

29 PANTAZI D, TSELEPIS AD. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms. Thromb Res. 2022 May;213 Suppl 1:S95–S102. Search in Google Scholar

30 MABUDIAN L, JORDAN JH, BOTTINOR W, HUNDLEY WG. Cardiac MRI assessment of anthracycline-induced cardiotoxicity. Front Cardiovasc Med. 2022 Sep 27;9:903719. Search in Google Scholar

31 SIMEK S, LUE B, RAO A, RAVIPATI G, VALLABHANENI S, ZHANG K, et al. Gender Differences in Diagnosis, Prevention, and Treatment of Cardiotoxicity in Cardio-Oncology. J Clin Med. 2022 Sep 1;11(17):5167. Search in Google Scholar

32 CEHIC DA, SVERDLOV AL, KOCZWARA B, EMERY J, NGO DTM, THORNTON-BENKO E. The Importance of Primary Care in Cardio-Oncology. Curr Treat Options Oncol. 2021 Oct 21;22(12):107. Search in Google Scholar

33 KOUTSOUKIS A, NTALIANIS A, REPASOS E, KASTRITIS E, DIMOPOULOS MA, PARASKEVAIDIS I. Cardio-oncology: A Focus on Cardiotoxicity. Eur Cardiol. 2018 Aug;13(1):64–69. Search in Google Scholar

34 KAAKEH Y, OVERHOLSER BR, LOPSHIRE JC, TISDALE JE. Drug-induced atrial fibrillation. Drugs 2012; 72 (12):617–1630. Search in Google Scholar

35 RAY JC, CHO P, DRAGON M, GRAHAM CG. A Case of 5-Fluorouracil-Induced Cardiac Arrest. J Emerg Med. 2016 Jan;50(1):e1–6. Search in Google Scholar

36 JOHNSON DB, BALKO JM, COMPTON ML, CHALKIAS S, GORHAM J, XU Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749–1755. Search in Google Scholar

37 MOSLEHI JJ, SALEM JE, SOSMAN JA, LEBRUN-VIGNES B, JOHNSON DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391:933. Search in Google Scholar

38 SALEM JE, ALLENBACH Y, VOZY A, BRECHOT N, JOHNSON DB, MOSLEHI JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med 2019;380:2377–2379. Search in Google Scholar

39 BROWN SA. Preventive Cardio-Oncology: The Time Has Come. Front Cardiovasc Med. 2020 Jan 10;6:187. Search in Google Scholar

40 GANATRA S, CHATUR S, NOHRIA A. How to Diagnose and Manage Radiation Cardiotoxicity. JACC CardioOncol. 2020 Nov 17;2(4):655–660. Search in Google Scholar

41 LANCELLOTTI P, SUTER TM, LÓPEZ-FERNÁNDEZ T, GALDERISI M, LYON AR, VAN DER MEER P, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019 Jun 7;40(22):1756–1763. Search in Google Scholar